Skip to main content
Sunday, November 15, 2026Nov 15

Alzheimer’s drug stirs hope for patients, worry for doctors

In this 2019 photo provided by Biogen, a researcher works on the development of the medication aducanumab in Cambridge, Mass. On Monday, June 7, 2021, the Food and Drug Administration approved aducanumab, the first new drug for Alzheimer's disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated treatment hasn't been shown to help slow the brain-destroying disease. (Biogen via AP)
In this 2019 photo provided by Biogen, a researcher works on the development of the medication aducanumab in Cambridge, Mass. On Monday, June 7, 2021, the Food and Drug Administration approved aducanumab, the first new drug for Alzheimer's disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated treatment hasn't been shown to help slow the brain-destroying disease. (Biogen via AP)

In the weeks since a new Alzheimer’s drug was approved, hopeful patients have bombarded Dr. Alireza Atri with calls and emails about a treatment that has sparked both excitement and skepticism.

They want to know if the drug might be right for them. Like many physicians, Atri has no easy answers.

“It’s not a simple yes or no,” said the neurologist at the Banner Sun Health Research Institute in Arizona.

It probably won’t be for a while. Doctors across the country are still trying to figure out who should receive the drug called Aduhelm, which, at best, slows the fatal disease marginally. Other drugs for Alzheimer’s disease only temporarily ease symptoms like memory problems, insomnia and depression.

While some clinics have already started giving the drug, many providers say it will take weeks or months before they are ready. Insurers – including the biggest bill payer for this drug, Medicare – still need to determine which patients to cover for a treatment that could cost more than $50,000 a year. And doctors worry that emotions will affect decisions by patients and families in seeking the drug.